StudyFinder

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

Search all categories
532 Study Matches

Personality Pathology in Youth

In this study, we hope to better understand the neural mechanisms underlying risk for personality disorders in adolescent youth. Understanding who is at risk for personality disorders early in development is important in order to develop preventative interventions.

Youth participants and their parent will be required to attend one in-person visit at our lab in Hershey, PA where youth participants will complete two computer tasks while EEG and cardiac data are collected. Youth participants will also complete questionnaires and a peer-interaction task with another peer their age. Parents will complete questionnaires and an interaction task with their child. Youth participants will complete remote surveys via a survey app for two weeks after the visit. This study includes 4 follow-up appointments (once every 6 months) which can be completed in-person or remotely via a Microsoft Teams meeting. These follow-up appointments will consist of a parent-child interaction task and surveys for parent and youth participants.

Up to $305

Yes
 

Dara Babinski
Breanne Tremblay - at bablab@pennstatehealth.psu.edu or 717-531-0003, ext=285969
Psychiatry and Behavioral Health (HERSHEY)
 

All
Younger than 18 years old
This study is also accepting healthy volunteers
STUDY00023682
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Children ages 10-13 and their parent
Current or past history of a mental health disorder OR no history of mental health disorder
Fluent in English

Exclusion Criteria:
Children under 10 or over 13
Youth or parent not fluent in English
Youth with intellectual or development disabilities
Youth with schizophrenia, bipolar disorder, or other psychotic disorders
Mental & Behavioral Health
Not applicable
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency–Associated Liver Disease With METAVIR Stage F1 Fibrosis

The goal of treatment with fazirsiran is to prevent and improve the build up of these abnormal proteins that cause liver injury and fibrosis by shutting down the production of Z-AAT. Decreasing Z-AAT build up in liver cells is important, as this protein has been clearly identified as the cause of liver injury in AATD.In this study, fazirsiran is being compared with a placebo for patients with AATD LD. A placebo is a liquid like fazirsiran but does not contain any active ingredients.

You will visit the study site approximately 12 times for blood sampling, computed tomography (CT) lung densitometry, lung function tests, FibroScans, ultrasounds, liver biopsy, esophagogastroduodenoscopy (EGD) study drug administration, and questionnaire completion.

Yes
 

Timothy Craig
Kristina Richwine - at krichwine@pennstatehealth.psu.edu or 717-531-4506
Medicine: Pulmonary, Allergy and Critical Care (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT06165341
STUDY00024618
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
The participant, of any sex, is aged 18 to 75 years, inclusive.
The participant must have a diagnosis of the PiZZ genotype AATD
The participant has evidence of METAVIR stage F1 liver fibrosis
An adult participant must have a body mass index (BMI) between 18.0 and 39.0 kg/m2, inclusive.
The participant is a nonsmoker

Exclusion Criteria:
The participant has evidence of ≥ F2 fibrosis based on liver biopsy during the screening period.
The participant has a history of varices based on a previous esophagogastroduodenoscopy.
The participant has portal vein thrombosis.
The participant has HIV infection as shown by the presence of anti-HIV antibody (seropositive).
The participant is pregnant or breastfeeding or intending to become pregnant before participating in this study, during the study.
Infectious Diseases & Immune System, Digestive Systems & Liver Disease
Experimental drug compared to a placebo/”sugar pill”
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Couples' Daily Lives with Chronic Back Pain

The purpose of this study is to learn more about the daily experiences of people with back pain and their spouse/partner. Participants and their spouse/partner will be interviewed by video using a tablet computer every 6 months for 2 years and will be asked to complete daily surveys twice a day for 30 days using the provided tablet computer. The daily surveys will take about 5 to 10 minutes to complete. Questions for the interviews and daily surveys focus on physical symptoms, feelings, activities, and interactions.

Video interviews using a tablet computer every 6 months for 2 years. Complete daily surveys twice a day for 30 days using a tablet computer.

295.00

No
 

Lynn Martire
Kari Whitehead - at couplesstudy@psu.edu or 814-865-7094
Human Development and Family Studies (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00013726
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Individuals with back pain at least 65 years or older
Experienced moderate or severe back pain for at least 3 months
Married or in a long-term relationship AND living with spouse or partner

Exclusion Criteria:
Does not work more than 20 hours a week outside the home
Arthritis & Rheumatic Diseases, Pain Management
I'm interested
Share via email

Remote testing for psychophysical studies of sensory perception and cognition

The purpose of this study is (1) to understand how the brain processes sensory information and (2) how this is affected by factors like blindness or synesthesia.

Participants will complete simple online tasks, for example judging differences in auditory pitch; processing visual and auditory stimuli in congruent and incongruent pairings; rating the sound-symbolic properties of either real words, pseudowords, or both; or discriminating between two stimuli on the basis of their structural properties over a change in their surface properties, and vice versa.

Amount varies depending on the study

No
 

Krishnankutty Sathian
Simon Lacey - at sathianlab@pennstatehealth.psu.edu
Neuroscience and Experimental Therapeutics (HERSHEY)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00015197
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Healthy adults over 18 years old
Normal or corrected-to-normal vision
No other sensory deficits
Adults who experience synesthesia

Exclusion Criteria:
Minors under the age of 18
Neurology, Language & Linguistics, Vision & Eyes
Not applicable
I'm interested
Share via email

Convergence of online machine learning policies for haptic feedback

The purpose of this study is to determine whether a machine-learning based algorithm for generating on-skin feedback can be trained quickly and can adapt quickly to changes in the environment. Participants will have an armband with vibration motors and microcontroller fitted to their right arm. They will provide indication about where around the circumference of their arm, they feel the vibration using a joystick. The joystick responses will be used to update a machine learning policy online such that the desired joystick responses match the actual ones by adjusting the levels of vibration in each motor.

There will be one in-person visit. You will have an armband with vibration motors and microcontroller fitted to your right arm. You will grasp a small joystick and move the stick around following the indications given by the vibration and/or visual display.

15

Yes
 

Katie Fitzsimons
Zachary Logan - at zal5@psu.edu
Mechanical and Nuclear Engineering (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00026482
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Able-bodied
Right-handed

Exclusion Criteria:
upper-limb injuries
neuromotor disorder
Not applicable
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

PSCI# 24-028 NRG-BR008: A PHASE III RANDOMIZED TRIAL OF RADIOTHERAPY OPTIMIZATION FOR LOW-RISK HER2-POSITIVE BREAST CANCER (HERO*)

This study will look at the differences in recurrence between patients who receive breast radiation after surgery to those who don't.

Participants will be required to come to all study visits, complete their radiation and chemotherapy treatments.

Yes
 

Leonard Tuanquin
PSCI-CTO@pennstatehealth.psu.edu 717-531-5471
Radiology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT05705401
STUDY00024714
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
The patient must be ≥ 40 years of age.
The patient must have an ECOG performance status of 0 ,1,
Histologically or cytologically confirmed invasive breast carcinoma.
The tumor must have been determined to be HER2-positive by current ASCO/CAP guidelines based on local testing results.
The tumor must have ER and PgR status assessed locally using current ASCO/CAP Guidelines.

Exclusion Criteria:
Definitive clinical or radiologic evidence of metastatic disease.
patients with a primary tumor >2 cm on pathologic examination of the surgical specimen
Patient planning for or status-post mastectomy.
Non-epithelial breast malignancies such as sarcoma or lymphoma.
Multicentric carcinoma (invasive cancer or DCIS)
Cancer
Experimental drug compared to an approved drug
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Pattern Learning in Human Adults

We are interested in what adults notice about stimuli that are presented to them. These stimuli typically consist of novel objects, abstract images, or made-up words.

Yes
 

Elisabeth Karuza
Elisabeth Karuza - at exk521@psu.edu
Psychology (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00010804
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age 18 and older
Fluent in English
Minimum High School Education
Normal or corrected-to-normal vision/ hearing

Exclusion Criteria:
No history of neurological injury or disorder
Those unable to consent, pregnant women, children, and prisoners will be excluded.
Language & Linguistics
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

Defining the role of slow eye movements on limb motor control

The purpose of this study is to define how eye movements contribute to eye-hand coordination. All procedures to be used in our study will be non-invasive. The task during the study will be performed with a robotic handle that participants will grasp with their right hand. They will interact with visual stimuli by moving the robotic handle. The robotic environment will attempt to simulate real-world mechanical interactions, such as those experienced during catching a ball. Our objective is to understand how the nervous system processes visual sensory information of moving objects through slow eye movements called smooth pursuit eye movements.

During this study, we will ask you to come to our laboratory located in 23 Recreation Building, Penn State University, on two days separated by a maximum of 48 hours. Both sessions will last approximately 90-120 minutes.We will ask you to perform an eye-hand coordination task using a robot. You will sit in a modified chair and grasp a handle that permits you to move your hand leftward, rightward, towards and away from your body. A display system will project visual targets into the same plane as your hands, which will allow you to interact virtually with the visual targets. These targets will move in the workspace. When the target comes in contact with your arm, the robot will apply a gentle force to mimic what you would typically experience when you catch a ball.

40

Yes
 

Tarkeshwar Singh
Oindrila Sinha - at osinha@psu.edu or 814-206-6260
Kinesiology (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00023321
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Participants should be between 18-65 years old.
Male and female participants who volunteer for the study and provide informed consent.
Participants will be right-hand dominant individuals.
They will have normal or corrected-to-normal vision.
Participants should be able to sit upright in a chair for long periods (up to 2 and a half hours) with rest.

Exclusion Criteria:
Any history of neurological disorders
Any history of musculoskeletal disorders.
Eye or vision problems.
Cognitive impairment such that informed consent cannot be obtained, or that participant would not be safe with the protocol.
Medication that could make the participant drowsy or tired during the experiment.
Neurology
Not applicable
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

Understanding the user experience of using consumer-facing digital symptom checkers

This is an interview study that examines how people use online symptom checker platforms or apps (e.g., WebMD, Ada, K health app, Your.MD) to self-diagnose or support the decision of whether and when to do a medical visit. The research procedure involves: 1) a short screening survey which helps us determine who are eligible to participate; 2) an audio‐taped interview with each eligible participant that will last approximately 30‐60 minutes online or offline near Penn State University Park. Each participant will be compensated with a $20 Amazon gift card for completing the interview.

Yes
 

Xinning Gui
yxy340@psu.edu
Information Sciences and Technology (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00013312
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Live in US
Speak English or Chinese
At least 18 years of age
Have used online symptom checker platforms or apps

Exclusion Criteria:
Less than 18 years old
Have never used any symptom checker
Vulnerable populations such as children, pregnant women, cognitively impaired adults, and prisoners
I'm interested
Share via email
Show 3 locations

Study Locations

Hide all locations
Location Contacts
Altoona, PA ,
Hershey, PA ,
State College, PA ,

Decision-Making in ADHD: An Evaluation of the Subjective Value of Rewards and Costs

Children with attention and behavior problems often need external rewards to motivate them to perform challenging tasks, but we don’t yet know much about how children weigh potential rewards and the effort required to obtain the rewards. This research is being done to find out how children with varying levels of ADHD symptoms value rewards and costs when making decisions about whether or not to perform a difficult task.

There will be one in-person visit. Children will complete two computerized cognitive tasks (thinking games), and will be able to earn prizes from the points they earn on these tasks. Parents will also be asked to complete a few questionnaires that should take about 25 minutes to finish. Children can earn up to $50 in compensation for completing the study.

$50

Yes
 

Dan Waschbusch
Thresia Casanova - at abc@pennstatehealth.psu.edu or 717-531-0003, ext=285966
Psychiatry and Behavioral Health (HERSHEY)
 

All
Younger than 18 years old
This study is also accepting healthy volunteers
STUDY00018076
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Children ages 8 to 12 years old
Children with normal or corrected vision
Caregiver and child must be fluent in written and spoken English
Willing to stop stimulant medications, when appropriate, for research testing

Exclusion Criteria:
Children who are younger than 8 years of age and children who are older than 12 years of age.
Current or past diagnosis of autism spectrum disorder, schizophrenia or other psychotic disorders.
Current use of non-stimulant medication due to its extended washout period.
Physical disabilities that are incompatible with completing laboratory tasks such as hearing impairments, or visual impairments that cannot be corrected with visual aids (i.e., glasses, contacts).
Children's Health, Mental & Behavioral Health
I'm interested
Share via email
Show 2 locations

Study Locations

Hide all locations
Location Contacts
Harrisburg, PA ,
Hershey, PA ,

PHASE I SAFETY ASSESSMENT OF HYPOFRACTIONATED POSTOPERATIVE RADIOTHERAPY (H-PORT) FOR INTERMEDIATE-RISK HEAD AND NECK CANCER

The purpose of this study is to test the good and bad effects of using hypofractionated radiation therapy. Hypofractionated radiation therapy could shrink or stabilize your cancer, but it could also cause side effects. The study doctors hope to learn if hypofractionated radiation therapy is safe and tolerable in patients with your type of cancer. You will receive radiation therapy for 4 weeks. You may also receive chemotherapy.

Participants will be required to receive radiation therapy for 4 weeks. Participants may also receive chemotherapy with cisplatin, carboplatin, or cetuximab.

Yes
 

Mitchell Machtay
PSCI-CTO at PSCI-CTO@pennstatehealth.psu.edu or 717-531-5471
Medicine: Hematology and Medical Oncology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT05540899
STUDY00022103
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Pathologically (histologically) proven diagnosis of squamous cell carcinoma (including variants such as verrucous carcinoma, spindle cell carcinoma, carcinoma NOS, etc.) of the head/neck
Clinical stage II, III or IVA squamous cell carcinoma of the oral cavity, oropharynx or larynx (AJCC 8th edition), including no distant metastases.
Total resection of the patient’s cancer (i.e. no residual disease after total resection of the patient’s cancer ).
One or more indications for postoperative radiotherapy, based upon pathologic findings: • Perineural invasion; • Lymphovascular invasion;
Zubrod Performance Status 0-1

Exclusion Criteria:
Recurrence of the study cancer.
History of systemic lupus erythematosus or systemic sclerosis (scleroderma).
Pregnancy and individuals unwilling to discontinue nursing.
Feeding tube (gastric or jejuno) at the time of registration.
Anticipated need for high-dose systemic chemotherapy (e.g. high dose q3-week cisplatin), multiple systemic therapy agents or immunotherapy. Weekly single-agent systemic therapy with cisplatin, carboplatin, or cetuximab is allowable.
Cancer
Not applicable
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

PSCI 23-092 EA8192 A Phase II/III trial of Durvalumab and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy

This trial is comparing outcomes of cisplatin eligible vs cisplatin ineligible high grade urothelial cancer patients treated with accelerated therapy vs gemcitabine and durvalumab followed by surgery.

Participants will need to complete all study visits, agree to having surgery and to make sure to tell the study team if they are having any side effects.

Yes
 

Monika Joshi
PSCI-CTO@pennstatehealth.psu.edu 717-531-5471
Medicine: Hematology and Medical Oncology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04628767
STUDY00023370
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Patient must be ≥18 years of age.
Patient must have the ability to understand and the willingness to sign a written informed consent document
Patient must have a diagnosis of high grade upper tract urothelial carcinoma proven by biopsy
Patients must not have any component of small cell/neuroendocrine carcinoma
Patients must not be pregnant or breast-feeding

Exclusion Criteria:
Patients must have no evidence of metastatic disease
Patient must not have another active (or within two years) second malignancy
Patient may have a history of resectable urothelial cancer
Patient must not have any uncontrolled illness
Patient must not have received prior systemic anthracycline therapy
Cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Cognitive and Social Factors Underlying Spoken Language Use

The central purpose of this research is to understand how language users produce and comprehend speech. To do this we ask participants to record speech, make judgments on the speech they hear, and work with a partner on simple language tasks.

Yes
 

Navin Viswanathan
Navin Viswanathan - at splaco@psu.edu
Communication Sciences and Disorders (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00011708
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
English Speakers
Between 18 and 65 years of age

Exclusion Criteria:
Those with diagnosed speech, hearing or language Issues
Language & Linguistics
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

A Phase 1/2, Open-label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects with Advanced or Metastatic Malignancies Harboring ALK, ROS1, or NTRK1-3 Alterations (CARE)

Repotrectinib for cancer that has returned or is not responding to treatment

If you agree to take part in this study, you will need to visit the study site regularly and follow the study procedures listed later in this document. You will be told what these procedures are and why they are needed. These procedures include interviews, exams, heart testing, tumor assessments, and blood and urine samples. You will be asked to take the study drug Repotrectinib. This is a capsule to be taken orally.

Yes
 

Valerie Brown
Suzanne Treadway - at streadway@pennstatehelath.psu.edu or 717-531-3097
Pediatrics: Hematology/Oncology (HERSHEY)
 

All
All
This study is NOT accepting healthy volunteers
NCT04094610
STUDY00014715
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
You have cancer that has returned or is not respondin g to treatment
You are positive for certain changes in your genes which we will test you for as needed

Exclusion Criteria:
1. You have gastrointestinal disease, such as Crohn’s disease,
Cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

The naturalistic reinforcement of obsessions and compulsions: An ecological momentary assessment study

The purpose of this study is to examine the relationship between sleep patterns, thoughts, behaviors, and emotions in obsessive-compulsive disorder (OCD). In the screening visit, participants will complete a brief interview and questionnaire to determine if they are eligible to participate in our study. Eligible participants will complete additional questionnaires and a training session on study procedures. Following this visit, for the next 7 days, participants will complete daily questionnaires and (for those selected to be in the sleep monitoring group) monitor their sleep by wearing a sleep watch. On day 4, participants will attend a brief compliance check Zoom visit where they will be informed about their overall compliance rate. Participants will be compensated with course credit. Findings from this research may help improve understanding of OCD symptoms and sleep.

Screening Visit: This can be conducted in person or over Zoom. During this visit, we will administer a short questionnaire and an interview to determine if you are eligible to participate in the study. If you are eligible, you will complete questionnaires and a training session on study procedures. You will also receive a sleep watch, which you will be asked to wear consequently for 7 days. This visit will take approximately 1 hour and 25 minutes.7 Day Monitoring: For the next 7 days, you will complete several, brief daily questionnaires (7 questionnaires/per day) on your smartphone. Questionnaires will take place generally every 2 hours starting from 10 a.m. to 10 p.m. You will also monitor your sleep by wearing a sleep watch and maintaining a daily sleep diary.Compliance Check (Day 4): On day 4, there will be a 5 minute compliance check Zoom meeting where you will be informed about your overall study compliance rate. Return and Debrief: At the end of the 7 days, you will be asked to return the sleep watch to our lab location (Moore Building) or schedule a pick-up time with a study team member. You will also receive an educational debriefing handout over email.

No
 

Valerie Swisher
Valerie Swisher - at vss5199@psu.edu
Division of Graduate Studies (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
STUDY00024470
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Meets criteria for Obsessive-Compulsive Disorder
Owns an iPhone or Android Smartphone
Fluency in English
Age 18 or older

Exclusion Criteria:
Younger than 18
Not able to consent or commit to study duration
Does not meet criteria for Obsessive-Compulsive Disorder
Meets criteria for certain conditions (e.g., schizophrenia)
Not fluent in English
Sleep Management, Mental & Behavioral Health
Not applicable
I'm interested
Share via email

Gaming Communities as Virtual Third Places: A Quantitative Assessment

This study will collect information about the use of gaming communities for social interaction.

Participants will be asked to complete a short survey.

No
 

Jeffrey Stone
Jeffrey Stone - at stonej@psu.edu or 610-285-5003
Information Sciences and Technology (LEHIGH VALLEY)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00021668
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Adults 18 years of age and older.

Exclusion Criteria:
Individuals under 18 years of age.
Mental & Behavioral Health
Not applicable
I'm interested
Share via email

One Talk at a Time - Anti-Racism

This is a psychological study to examine the effect of a new intervention that provides parents with tools to speak with their kids about race, racism, and privilege.Participants will complete a 2-3 hour long program and answer questionnaires over the course of 6-8 weeks. The total time required for this study is approximately 4.5 hours for parents and 2 hours for children. Parents can earn up to $165 and children can earn up to $50.

Parents and children will both be asked to participate, and all participation will be remote.Over the course of 6-8 weeks, parents will answer 3 sets of questionnaires in addition to completing 2-3 hour long interactive program. Parents will also be asked to participate in a recorded discussion task with their child, and will be invited back for a short interview as the final task.Children will answer 2 sets of questionnaires at the beginning and end of the study, and will also participate in the recorded discussion task with their parents.

215

No
 

Chardee Galan
Chardee Galan - at dreamlab@psu.edu or 626-205-5563
Psychology (UNIVERSITY PARK)
 

All
All
This study is also accepting healthy volunteers
STUDY00023214
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Non-Hispanic, White parent and child
Child between the ages of 10-14 years old
Child in 5th through 8th grade
Parent and youth are fluent in English
Parent and youth have access to devices with WiFi

Exclusion Criteria:
Parent or youth identify as any race/ethnicity other than non-Hispanic White, including multiracial individuals that identify as White
Family does not have reliable internet access or access to a device that can appropriately display the virtual program.
Parent or children does not speak or read sufficient English
Youth or parent/caregiver has an intellectual disability, autism spectrum disorder, or other disorder that may limit ability to complete study (surveys and interviews require sustained attention, mental processing, and comprehension)
Children's Health, Education, Mental & Behavioral Health
Not applicable
I'm interested
Share via email

Effects of increased interstitial pressure on venous distension reflex

The purpose of this study is determine if an increase in interstitial pressure has an effect on the venous distension reflex.

This study involves a single visit with 2 trials.You will receive an infusion of saline in your arm before and after a procedure to cause a temporary swelling in your arm.

You will receive $25 per hour for your participation in this research study

Yes
 

Takuto Hamaoka
Cheryl Blaha - at cblaha@pennstatehealth.psu.edu or 717-531-1605
Heart and Vascular Institute (HERSHEY)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00019302
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Men and women of any race or ethnicity
Healthy (no major disease)
Between 21-60 years old
Weigh over 110 punds

Exclusion Criteria:
Are not between 21-60 years old
Pregnant or nursing women
Have a major disease (heart, lungs, kidney, diabetes, cancer)
High blood pressure
metal implants or claustrophobic
Men's Health, Heart & Vascular, Women's Health
Not applicable
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Exploring the Concreteness Effect in Expressive and Receptive Language Measures in Healthy Aging as a Comparison for Persons with Aphasia

The concreteness effect is the finding that individuals are faster and more efficient at processing concrete words (e.g., "dog") than abstract words (e.g., "wisdom"). The study will investigate the presence and strength of the concreteness effect in neurologically intact older adults. This data will be used as a control comparison for a group of people with aphasia, a language disorder that commonly results from left hemisphere stroke.

Participants will be asked to complete language and cognition tests that measure attention, memory, problem solving, and language processing on the computer. Participants will be asked to complete two Zoom sessions, each lasting approximately 1.5 hours.

30

No
 

Anna Serrichio
Anna Serrichio - at acs36@psu.edu
Division of Graduate Studies (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00023820
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Native English Speaker
At least a high school education
40 years of age or older
Access to device with keyboard and internet connection to participate in Zoom sessions

Exclusion Criteria:
History of neurological, developmental, or psychiatric disorders
Below 40 years of age
Language & Linguistics
Not applicable
I'm interested
Share via email

A Phase III, Randomised, Double-blind Study to Evaluate theEffect of Balcinrenone/Dapagliflozin, Compared withDapagliflozin, on the Risk of Heart Failure Events andCardiovascular Death in Patients with Heart Failure and ImpairedKidney Function (BalanceD-HF, D6402C00012))

The study is being done to determine whether dalcinrenone/dapagliflozin is superior to dapagliflozin in reducing the risk of cardiovascular death and heart failure events with and without hospitalization

Sign consent form, attend scheduled study visits, undergo an echocardiogram (if applicable) and electrocardiogram, complete pregnancy test (if applicable), undergo physical examination, vital signs, height and weight measurements, complete study questionnaires, provide urine and blood samples for the study, take study medication as directed.

up to $1,600

Yes
 

Umar Farooq
PSHVIResearchCoordinators@pennstatehealth.psu.edu 717-531-5967
Medicine: Nephrology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT06307652
STUDY00024754
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
recent heart failure event
being treated for heart failure
undergoing treatment for decreased kidney function

Exclusion Criteria:
chest discomfort, heart attack or stroke within last 3 months
major heart surgery within the past 3 months
complicated heart defects at birth or severe uncorrected valve disease
Kidney & Urinary System, Heart & Vascular
Experimental drug compared to an approved drug
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Student Housing Assessment

The primary objectives are to identify why students choose where they live; what is their perception of value for housing; is this value based on their home city/state/country; how are they paying for housing costs; if their parents are paying for the housing, what perception of value do the parents have, what is their economic status, what is their home owning status, etc.

No
 

Mallory Meehan
Mallory Meehan - at mmm446@psu.edu
Institute for Real Estate Studies (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00010798
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Undergraduate Student
Graduate Student
Enrolled and living at University Park

Exclusion Criteria:
Non-student
Education
I'm interested
Share via email

Expanding Family Foundations to 2nd-Time Parenthood - Focus Group

This focus group study, funded by Penn State's Social Science Research Institute, brings together couples with preschool-aged firstborns who are pregnant with their 2nd child or who have given birth to their 2nd child within the last 12 months. Couples will be interviewed about how they worked together as a team (as coparents) to prepare their firstborn for the birth of the second child and to prepare themselves for 2nd-time parenthood.

Yes
 

Douglas Teti
Douglas Teti - at dmt16@psu.edu or 814-863-9570
Human Development and Family Studies (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00015968
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
1.Two-caregiver families, any race or ethnicity, with one or two children: a.One subgroup with one child < 6 years of age and pregnant with a 2nd child b.One subgroup with one child < 6 years of age and an infant between 1-to-12 months of age.
2.Each caregiver is over 18 years of age.
3.Caregivers are living together in the same household and are either married or living with a partner.
4.Families living independent of parents’ families of origin.
5.Both caregivers fluent in communicating in English.

Exclusion Criteria:
1.One or the other caregiver cannot understand or speak English
2.Caregivers are under 18 years of age.
3.Caregivers not living together
4.Caregivers not living independently of their families of origin
5.Single-parent families with no live-in partner.
Children's Health, Prevention, Mental & Behavioral Health
I'm interested
Share via email
Show 17 locations

Study Locations

Hide all locations
Location Contacts
Altoona, PA ,
Carlisle, PA ,
DuBois, PA ,
Erie, PA ,
Greater Philadelphia Area, PA ,
Greater Pittsburgh Area, PA ,
Harrisburg, PA ,
Hazleton, PA ,
Hershey, PA ,
Mont Alto, PA ,
Reading, PA ,
Schuylkill Haven, PA ,
Sharon, PA ,
State College, PA ,
Wilkes-Barre/Scranton Area, PA ,
Williamsport, PA ,
York, PA ,

A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2002 in Participants With Hereditary Angioedema

This study will investigate the effects of NTLA-2002 on people with Hereditary Angioedema (HAE). NTLA-2002, which consists of a CRISPR/Cas9 gene editing system, is designed to limit production of plasma kallikrein in the liver cells by acting on the KLKB1 gene. This means NTLA-2002 would permanently change the DNA in the liver cells so less plasma kallikrein would be produced. Lower levels of plasma kallikrein may result in fewer HAE attacks.

During part 1 of the study, participants will either be given NTLA-2002 or placebo (no active ingredients) as an intravenous infusion. Participants will have the option to receive the opposite infusion about 28 weeks later. This study involves getting pre-medications to reduce the chance of an HAE attack and a reaction to the infusion. Study assessments will be preformed to monitor safety. Daily electronic diaries will be completed to monitor for HAE attacks. Also quality of life questionnaires will be completed. If part 1 and part 2 are completed, there are 22 visits. Some of those visits can occur over the phone.

Yes
 

Timothy Craig
Kara Grim - at kgrim@pennstatehealth.psu.edu or 717-531-4513
Medicine: Pulmonary, Allergy and Critical Care (HERSHEY)
 

All
All
This study is NOT accepting healthy volunteers
NCT06634420
STUDY00025612
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Males or females 16 years of age or older and Ability to understand and the willingness to sign a written informed consent document
Diagnosis of Hereditary Angioedema Type 1 or Type 2
Access to rescue treatment for Hereditary Angioedema

Exclusion Criteria:
Liver cirrhosis
history of drug or alcohol abuse in the past 3 years
history of active cancer in the past 3 years
Infectious Diseases & Immune System, Allergies
Experimental drug compared to a placebo/”sugar pill”
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Stepping and Balance in Young and Older Healthy Adults Walking on Winding Paths

As we walk, we have to stay balanced to avoid falling while also being able to maneuver along various paths that are most often not straight. This study will test younger and older healthy adults walking on paths of varying complexity and difficulty to determine how they negotiate achieving these various task goals. We predict that older adults will have greater difficulty successfully completing these tasks and will use different motor control strategies to do so.

There will be one in-person visit (easy free parking is available). This visit should last no more than 2 hours total.We will ask you to complete a health history questionnaire, do some basic visual assessments, and physical assessments. Your height, weight, and blood pressure will also be taken. After screening, you will walk on a treadmill in a virtual reality environment. We will ask you to walk on various different paths. Your task will be to stay on a path that may be windy and/or difficult to see. Treadmill walking will take less than an hour and you can take rest breaks as needed.

$30.00

Yes
 

Jonathan Dingwell
Sarah Overby - at seo5285@psu.edu
Kinesiology (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00025096
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age 18-35, or 65 or older
No medications or health conditions that significantly impair your walking ability.
Body Mass Index (BMI) more than 18 and less than 30
Normal corrected vision (≥ 20/40)
Able to walk un-assisted for at least 5 minutes without shortness of breath, chest pain, or joint pain in the legs, neck, or back

Exclusion Criteria:
Not meeting any of the above
Prevention
Not applicable
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

PSCI 24-139 NRG-BN013: PHASE III TRIAL OF SINGLE FRACTION STEREOTACTIC RADIOSURGERY (SRS) VERSUS FRACTIONATED

This trial will examine if disease progression improves with Fractionated vs. Steriotactic Radiosurgery.

Participants must agree to the type of radiation they are randomized, keep all appoiintments and rpoert any side effects.

Yes
 

Sean Mahase
PSCI-CTO@pennstatehealth.psu.edu 717-531-5471
Radiation Oncology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT06500455
STUDY00026009
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Pathologically (histologically or cytologically) proven diagnosis of one of the following solid tumor malignancies within 5 years prior to registration:
Patients must have at least 1 and up to 8 total intact brain metastases
All brain metastases must be located outside of the brainstem
No more than 2 lesions planned for resection
No known leptomeningeal disease

Exclusion Criteria:
Not Pregnant and Not Nursing
No prior radiotherapy to the brain
No active infection
No hepatic insufficiency
No chronic obstructive pulmonary disease exacerbation
Cancer
Not applicable
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

A011801 THE COMPASSHER2 TRIALS (COMPREHENSIVE USE OF PATHOLOGIC RESPONSE ASSESSMENT TO OPTIMIZE THERAPY IN HER2-POSITIVE BREAST CANCER): COMPASSHER2 RESIDUAL DISEASE (RD), A DOUBLE-BLINDED, PHASE III RANDOMIZED TRIAL OF T-DM1 AND PLACEBO COMPARED WITH T-DM1 AND TUCATINIB (PSCI# 21-155)

The purpose of this study is to compare the usual treatment with T-DM1 alone to T-DM1 plus tucatinib. The addition of tucatinib to the usual treatment could prevent the breast cancer from returning

The purpose of this study is to compare the usual treatment with T-DM1 alone to T-DM1 plus tucatinib. The addition of tucatinib to the usual treatment could prevent the breast cancer from returning.

Yes
 

Cristina Truica
psci-cto@pennstatehealth.psu.edu 717-531-5471
Medicine: Hematology and Medical Oncology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04457596
SITE00001048
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age = 18 years or older (male or female)
ECOG Performance Status 0-1
Patients must have received neoadjuvant chemotherapy with one of the following regimens: THP, TMP, AC-TH(P); TCH(P); FAC-TH(P), or FEC-TH(P).
HER2-positive breast cancer per pathology
Prior treatment must have consisted = 6 cycles of chemotherapy and HER2-directed therapy, with a total duration of = 12 weeks, including at least 9 weeks of preoperative taxane and trastuzumab with or without pertuzumab (or FDA-approved biosimilars).

Exclusion Criteria:
Prior receipt of T-DM1 in the neoadjuvant setting is not allowed.
Patients with known active and/or untreated Hepatitis B or Hepatitis C or chronic liver disease are ineligible.
Stage IV (metastatic) breast cancer
History of any prior (ipsi- or contralateral) invasive breast cancer within 3 years of registration
Patients with ER+ HER2+ residual invasive disease that is lymph node-negative per the surgical pathology report
Cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Nurse Situation Awareness in ICUs

This is an interview and survey study that will examine how the design of ICU warning information system influence nurses situation awareness.

This study aims to understand how the design factors of warning information system influence nurse situation awareness in ICUs. You will participate an online interview study and fill out two questionnaires. The study takes 1-2 hours.

$30

No
 

Yiqi Zhang
Yiqi Zhang - at yuz450@psu.edu
Industrial and Manufacturing Engineering (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00020979
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Be a practicing nurses or a nursing student who has clinical experience in ICU settings

Exclusion Criteria:
NA
Children's Health, Education, Mental & Behavioral Health
Not applicable
I'm interested
Share via email

Phase 1/2 Study to Evaluate Palbociclib (IBRANCE®) in Combination with Irinotecan and Temozolomide or in Combination with Topotecan and Cyclophosphamide in Pediatric Patients with Recurrent or Refractory Solid Tumors

A study of the safety of palbociclib with irinotecan and temozolomide and palbociclib with topotecan and cyclophosphamide for children with solid tumors that returned or did not respond to previous treatment.

If you join the study, you will be assigned to receive either palbociclib in combination with backbone chemotherapy of IRN and TMZ or the backbone chemotherapy (IRN and TMZ). You may be asked to provide biological samples (such as blood or urine or tumor tissue sample) and undergo procedures that might be different from a regular medical examination. This study will involve screening, treatment, and follow up period. During screening, the study doctor will determine whether you are eligible for the study. If you are eligible and are enrolled into the study, you will be required to visit the study doctor on days 1 to 5 of each 21-day cycle and on day 14 for the first 2 cycles to undergo study assessments and to provide information about your health.

Yes
 

Valerie Brown
Suzanne Treadway - at streadway@pennstatehealth.psu.edu or 717-531-3097
Pediatrics: Hematology/Oncology (HERSHEY)
 

All
All
This study is NOT accepting healthy volunteers
NCT03709680
STUDY00012769
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Have a solid tumor that has returned or did not respond to previous treatment
Ages ≥2 and <21

Exclusion Criteria:
Prior intolerability to the chemo drugs used in this study
Cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Cabazitaxel with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease following Docetaxel: the CHAARTED2 Trial

To assess whether the addition of 6 cycles of cabazitaxel to abiraterone acetate in patients with CRPC that have previously received docetaxel and ADT for HSPC can improve PFS compared toabiraterone acetate alone.

To assess whether the addition of 6 cycles of cabazitaxel toabiraterone acetate in patients with CRPC that have previouslyreceived docetaxel and ADT for HSPC can improve PFS compared toabiraterone acetate alone.

Yes
 

Monika Joshi
PSCI-CTO@pennstatehealth.psu.edu 717-531-5471
Medicine: Hematology and Medical Oncology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03419234
SITE00000449
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age ≥ 18 years
Histologically confirmed diagnosis of prostate cancer (adenocarcinoma of the prostate).
Previous chemotherapy with at least 3 cycles of docetaxel for hormone-sensitive metastatic prostate cancer.
Metastatic disease as evidenced by the presence of soft tissue and/or bone metastases on imaging studies (CT/MRI of abdomen/pelvis, bone scintigraphy or NaF PET/CT).
Ability to swallow abiraterone acetate tablets as a whole.

Exclusion Criteria:
Any prior chemotherapy or AR-directed therapy for CRPC, (e.g. docetaxel, cabazitaxel, mitoxantrone, abiraterone
Pure small cell or other variant (non-adenocarcinoma) prostate cancer histology for which treatment with abiraterone would not be considered appropriate.
Patients may not be receiving other therapeutic investigational agents or be receiving concurrent anticancer therapy other than standard androgen deprivation therapy.
Any medical condition for which prednisone (corticosteroid) is contraindicated.
Active infection requiring treatment with antibiotics.
Cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Children's appetite regulation study

The purpose of this study is to determine whether girls and boys regulate their appetites differently. Children will attend 1, 3 hour session in the laboratory, complete some surveys and health measures, donate saliva, and eat pizza.

Children will come to the lab for a 3.5 hour session where they will wear a heart rate monitor, conduct some surveys, have their veggie intake measured, provide some saliva, and eat some pizza. Parents will attend the lab visit with the child and complete questionnaires about feeding and the home environment.

$50 plus travel costs for &gt; 20 miles from lab

Yes
 

Kathleen Keller
Rhea Sarma - at rvs6115@psu.edu
Nutritional Sciences (UNIVERSITY PARK)
 

All
All
This study is also accepting healthy volunteers
NCT00000000
STUDY00025564
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age 4-6 years
Healthy without food allergies
Parent in charge of feeding able to attend with child

Exclusion Criteria:
Younger than age 4 or older than age 6 years
Children with medical problems or taking a prescription medication that may affect appetite
Children who are not willing to eat pizza in the laboratory
The parent in charge of feeding decisions cannot attend with the child
Children's Health, Food & Nutrition
Not applicable
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,